$CURR: Vitamin D is one of the most important factors for maintaining health and wellness. It is very significant to see the success CURR is reporting with its oral thin film recent Vitamin D dosing study.
“The findings for our proprietary, oral thin film Vitamin D, which we brand as ImmunD3 NutriStrips, is quite remarkable for its ability to improve bone health and reduce complications in pediatric patients and brings additional hope to the parents and their children who undergo HSCT stem cell therapy, for life-threatening diseases,” said CURE Pharmaceutical CEO Rob Davidson. “If we can reduce the risks of complications by bringing these children up to optimal Vitamin D levels before surgery, and in the acute post-transplantation period, we’ve helped to reduce pain and suffering and potentially saved lives.”
Positive Findings from Study at Cincinnati Children’s Hospital Medical Center Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT) https://finance.yahoo.com/news/cure-pharmaceutical-announces-positive-findings-174200049.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
